Scholar Rock Holding Corporation (SRRK) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Cambridge, MA, アメリカ. 現CEOは David L. Hallal.
SRRK を有する IPO日 2018-05-25, 128 名の正社員, に上場 NASDAQ Global Select, 時価総額 $5.69B.
Scholar Rock Holding Corporation is a biopharmaceutical company focused on discovering and developing medicines that target protein growth factor signaling pathways to treat serious diseases. The company's lead candidate, Apitegromab, a myostatin activation inhibitor, has completed Phase 3 clinical trials for spinal muscular atrophy treatment, while SRK-181 is in Phase 1 development for checkpoint inhibitor-resistant cancers. Scholar Rock maintains a strategic collaboration with Gilead Sciences to develop transforming growth factor beta inhibitors for fibrotic diseases, with a broader pipeline addressing neuromuscular disorders, oncology, and fibrosis indications. Founded in 2012 and headquartered in Cambridge, Massachusetts, the company aims to transform patient outcomes across multiple serious disease areas through its targeted therapeutic approach.
